Moreover, downregulation of XPC could also enhance the sensitivity of ovarian cancer to cisplatin (Zhang et al., 2015), and XPC SNPs were correlated with survival outcomes of ovarian cancer treated with platinum-based chemotherapy (Kang et al., 2013). This evidence concerns the gene XPC and ovarian cancer.